The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.
Paper No. 17
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte JOHN L. RIDIHALGH
__________
Appeal No. 2001-1150
Application No. 09/167,764
__________
ON BRIEF
__________
Before WILLIAM F. SMITH, SCHEINER, and GREEN, Administrative Patent
Judges.
GREEN, Administrative Patent Judge.
DECISION ON APPEAL
This is a decision on appeal under 35 U.S.C. § 134 from the examiner’s
final rejection of claims 1, 3-5 and 8-10. Claims 1 and 6 are representative of the
subject matter on appeal, and read as follows:
1. A therapeutic agent for treating patients afflicted with chronic fatigue
syndrome (CFS), which comprises:
in a pharmaceutically-acceptable carrier, cytokine-producing cells having been
produced by the step of subjecting cells derived from autologous lymph nodes
excised from patients afflicted with CFS to mitogenic stimulation in the presence
of interleukin-2 (IL-2) and anti-CD3 monoclonal antibody in serum-free media for
their expansion.
6. A method for treating patients afflicted with chronic fatigue syndrome
(CFS), which comprises:
Page: 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007